In 2023, an epidemiological investigation, conducted on the Ipsos nonalcoholic steatohepatitis (NASH) therapy monitor database regarding real clinical practice in the management of patients with NASH, highlighted that 28% of these patients were prescribed angiotensin-converting enzyme (ACE) inhibitors (ACEIs) [1]. The gene discussed is ACE; the disease is metabolic dysfunction-associated steatohepatitis.